Discover selected analytical methods for diabetes and obesity research by joining our latest webinar. Our speakers address a range of interesting topics, including the quantification of peptides that regulate metabolism and the use of stable isotope tracers in clinical trials. View the on-demand version for free and download the presentation slides with some additional comments from our experts Dr. Thomas Pieber, Dr. Reingard Raml and Dr. Christoph Magnes.
In the latest issue of the Journal MABS, Florie Le Prieult and colleagues from AbbVie Germany published latest results they observed after measuring concentrations of a monoclonal anitbody - trastuzumab - in the interstitial brain fluid (ISF) of awake and freely moving mice. The only currently available methods for extracting ISF, are Microdialysis (MD) and cerebral open flow microperfusion (cOFM).
For the first time, both methods were compared at a technical and performance level for the collection of large molecules in rodents. They found 10-fold higher absolute concentrations in cOFM samples compared to MD. In vivo recovery revealed an increased extraction of trastuzumab at low flow rates and a 6-fold higher absolute concentration at steady state than initially calculated with the in vitro recovery.
The authors conclude that the “standardization of these complex methods makes the unraveling of ISF concentrations attainable for various diseases and modalities, starting in this study with mAbs, but extending further in the future to RNA therapeutics, antibody-drug conjugates, and even cell therapies.”
We are pleased to announce that JOANNEUM Research HEALTH has successfully renewed the GLP certification for its analytical laboratory, strengthening its positioning as a competent and professional partner for the pharmaceutical industry. Our analytical laboratory develops analytical methods in the research areas of bioanalytics and metabolomics and combines scientific competence with GLP/GCP standards for both complex research projects and drug development programs. We focus on the high quality of analytical results that are both traceable and tailored to the needs of our customers.
Download: GLP Certificate
We are pleased to announce that we have prepared some useful content from our Webinar "Informed decisions in dermal drug development with dOFM". Please find below a collection of valuable insights, a comprehensive Q&A Catalogue and easy access to all relevant resources. Browse through a collection of questions raised by our listeners during the live webinar to see which topics are particularly relevant for our audience. Take a more detailed look at the slides and download the presentation including some additional notes from our dOFM experts.
In a cooperative contract research project, HEALTH and Med Uni Graz have tested a new insulin in a clinical phase 1 study on behalf of Arecor. The study, in which HEALTH was responsible for insulin analysis, statistical evaluation, clinical data management, and quality management, showed that the new insulin enters the bloodstream more quickly and thus also acts faster. As a result, blood glucose control in type 1 diabetics is optimized and dangerous hyper- and hypoglycemia can be avoided. The study results are now published in the top-ranking Journal Diabetes Care.
This new type of fast-acting insulin is an important step in the development of an artificial pancreas. HEALTH is proud to support our clients with new developments to further improve the lives of people with diabetes.
Dr Thomas Birngruber and Dr Frank Sinner will present valuable insights on improved formulation screening and local dermal PK and PD using dOFM sampling. This webinar will give you a concise overview of dOFM capabilities and introduce possible setups for preclinical and clinical studies. We will present several case studies for drug development, biomarker discovery and bioequivalence assessment. More information
Our experts will answer all your questions personally, such as: